BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3323260)

  • 41. Esmolol for the management of pediatric hypertension after cardiac operations.
    Wiest DB; Garner SS; Uber WE; Sade RM
    J Thorac Cardiovasc Surg; 1998 Apr; 115(4):890-7. PubMed ID: 9576226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
    Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
    J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Esmolol in anesthesiology: pharmacology and indications].
    Fita G; Gomar C; Rovira I
    Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.
    Shaffer JE; Quon CY; Gorczynski RJ
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):187-92. PubMed ID: 2452313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
    Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
    J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.
    Das G; Tschida V; Gray R; Dhurandhar R; Lester R; McGrew F; Askenazi J; Kaplan K; Emanuele M; Turlapaty P
    J Clin Pharmacol; 1988 Aug; 28(8):746-50. PubMed ID: 2905710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experience with atenolol in patients with chronic liver disease.
    Kirch W; Schäfer-Korting M; Mutschler E; Ohnhaus EE; Braun W
    J Clin Pharmacol; 1983 Apr; 23(4):171-7. PubMed ID: 6863581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiarrhythmic activity of esmolol (ASL-8052)--a novel ultra-short acting beta-adrenoreceptor blocking agent.
    Klein G; Wirtzfeld A; Alt E; Steck J; Saunders R; Hulse J; Kartzinel R; Lee R; Laddu AR
    Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):112-7. PubMed ID: 6142005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias.
    Schwartz M; Michelson EL; Sawin HS; MacVaugh H
    Chest; 1988 Apr; 93(4):705-11. PubMed ID: 2894920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction: The BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial.
    Er F; Dahlem KM; Nia AM; Erdmann E; Waltenberger J; Hellmich M; Kuhr K; Le MT; Herrfurth T; Taghiyev Z; Biesenbach E; Yüksel D; Eran-Ergöknil A; Vanezi M; Caglayan E; Gassanov N
    JACC Cardiovasc Interv; 2016 Feb; 9(3):231-240. PubMed ID: 26847114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Esmolol in acute ischemic syndromes.
    Mitchell RG; Stoddard MF; Ben-Yehuda O; Aggarwal KB; Allenby KS; Trillo RA; Loyd R; Chang CT; Labovitz AJ
    Am Heart J; 2002 Nov; 144(5):E9. PubMed ID: 12422138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia.
    Johansen JW; Flaishon R; Sebel PS
    Anesthesiology; 1997 Feb; 86(2):364-71. PubMed ID: 9054254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Characteristics and clinical use of esmolol].
    Ravussin P
    Minerva Anestesiol; 1992 Apr; 58(4 Suppl 1):77-9. PubMed ID: 1352393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.
    Askenazi J; MacCosbe PE; Hoff J; Turlapaty P; Hua TA; Laddu A
    J Clin Pharmacol; 1987 Aug; 27(8):567-73. PubMed ID: 2888793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension.
    Gray RJ; Bateman TM; Czer LS; Conklin C; Matloff JM
    Am J Cardiol; 1987 Apr; 59(8):887-91. PubMed ID: 2881481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The hemodynamic effects of a treatment with beta-receptor blockers during coronary surgery. A comparison between acebutolol and esmolol].
    Kling D; Boldt J; Zickmann B; Dapper F; Hempelmann G
    Anaesthesist; 1990 May; 39(5):264-8. PubMed ID: 1972611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of propofol infusions in patients with cirrhosis.
    Servin F; Cockshott ID; Farinotti R; Haberer JP; Winckler C; Desmonts JM
    Br J Anaesth; 1990 Aug; 65(2):177-83. PubMed ID: 2223333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.
    Koutouzis M; Nikolidakis S; Grigoriadis A; Koutsogeorgis D; Kyriakides ZS
    Drugs Aging; 2006; 23(8):673-80. PubMed ID: 16964989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.